HBM Holdings Ltd. (HK:2142)
:2142
Want to see HK:2142 full AI Analyst Report?
Top Page
HBM Holdings Ltd.
(2142)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$14.00
▲(15.89% Upside)
Action:Reiterated
Date:05/06/26
The score is primarily supported by a strong 2025 financial turnaround (profitability, revenue growth, improved leverage, and positive free cash flow). Offsetting this are historically volatile results and a mixed technical picture, while valuation cannot be reliably assessed due to missing/invalid P/E and dividend yield data.
Positive Factors
Strong 2025 profitability
The company delivered very high gross (~93%) and net (~58%) margins in 2025 alongside a large earnings rebound. Such margin expansion signals scalable economics and pricing power in core offerings, supporting durable cash generation and reinvestment capacity if revenue levels hold.
Negative Factors
Historical earnings and cash volatility
Past multi-year swings in revenue, margins, and cash flow indicate the company’s results are sensitive to business-cycle, product adoption, or execution variability. This volatility raises execution risk that a single strong year may not persist, complicating forecasting and capital allocation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong 2025 profitability
The company delivered very high gross (~93%) and net (~58%) margins in 2025 alongside a large earnings rebound. Such margin expansion signals scalable economics and pricing power in core offerings, supporting durable cash generation and reinvestment capacity if revenue levels hold.
Read all positive factors
HBM Holdings Ltd. (2142) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.04B
Dividend YieldN/A
Average Volume (3M)8.63M
Price to Earnings (P/E)13.5
Beta (1Y)1.12
Revenue Growth314.00%
EPS Growth3032.07%
CountryHK
Employees183
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.07
Shares Outstanding899,273,740
10 Day Avg. Volume6,681,047
30 Day Avg. Volume8,634,233
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.37
Price to Sales (P/S)7.82
P/FCF Ratio17.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.97Price Target Upside65.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$230.28M
HBM Holdings Ltd. Business Overview & Revenue Model
Company Description
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal ...
HBM Holdings Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
73
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 158.21M | 38.10M | 89.50M | 40.66M | 4.31M |
| Gross Profit | 147.13M | 33.61M | 87.47M | 40.53M | 4.17M |
| EBITDA | 83.23M | -2.08M | 31.18M | -130.21M | -130.84M |
| Net Income | 91.47M | 2.78M | 22.80M | -137.27M | -137.88M |
Balance Sheet | |||||
| Total Assets | 500.26M | 215.01M | 228.48M | 232.12M | 282.36M |
| Cash, Cash Equivalents and Short-Term Investments | 401.90M | 167.22M | 140.72M | 171.71M | 216.30M |
| Total Debt | 81.77M | 61.34M | 66.01M | 90.93M | 19.47M |
| Total Liabilities | 133.14M | 90.96M | 108.85M | 139.62M | 59.45M |
| Stockholders Equity | 367.13M | 124.45M | 119.99M | 92.83M | 223.19M |
Cash Flow | |||||
| Free Cash Flow | 69.58M | 30.44M | -21.60M | -118.40M | -139.81M |
| Operating Cash Flow | 81.33M | 30.68M | -19.12M | -99.96M | -125.61M |
| Investing Cash Flow | -179.02M | 6.55M | 28.09M | 137.59M | -76.90M |
| Financing Cash Flow | 157.35M | -10.24M | -29.14M | 70.58M | 1.59M |
HBM Holdings Ltd. Technical Analysis
Negative
12.08
Price Trends
13.06
Negative
12.74
Negative
13.07
Negative
Market Momentum
-0.22
Positive
38.46
Neutral
22.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2142, the sentiment is Negative. The current price of 12.08 is below the 20-day moving average (MA) of 13.25, below the 50-day MA of 13.06, and below the 200-day MA of 13.07, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 38.46 is Neutral, neither overbought nor oversold. The STOCH value of 22.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2142.
HBM Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$11.04B | 13.52 | 17.09% | ― | 314.00% | 3032.07% | |
55 Neutral | HK$7.44B | ― | 11.49% | ― | 20.39% | 104.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.21B | -15.87 | -6.26% | ― | -11.65% | -169.40% | |
51 Neutral | HK$8.25B | 9.33 | 24.17% | ― | 154.21% | ― | |
50 Neutral | HK$12.38B | -11.03 | -64.19% | ― | -33.37% | -344.90% |
* Healthcare Sector Average
HK:2142
HBM Holdings Ltd.
11.79
2.09
21.55%
HK:9966
Alphamab Oncology
8.55
-0.43
-4.79%
HK:2157
Lepu Biopharma Co. Ltd. Class H
4.43
-0.04
-0.89%
HK:2256
Abbisko Cayman Limited
10.00
1.19
13.51%
HK:2616
CStone Pharmaceuticals
7.70
4.04
110.38%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.32
-4.68
-42.55%
HBM Holdings Ltd. Corporate Events
HBM Holdings Sets 2026 AGM to Approve Results, Board Changes and Share Issue Mandate
Apr 28, 2026
HBM Holdings Limited has called its annual general meeting for 25 June 2026 in Shanghai, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and the related reports of the dire...
HBM Holdings Grants Performance-Linked Share Awards to Employee
Mar 31, 2026
HBM Holdings Limited has granted 103,000 share awards to a single non-connected employee under its existing share award scheme, with no exercise price and based on a market price of HK$13.10 per share at the grant date. The awards, which do not re...
HBM Holdings’ 2025 Profit Surges as Global Pharma Alliances Deepen
Mar 30, 2026
HBM Holdings reported a sharp increase in revenue to US$157.98 million and profit to US$92.22 million for 2025, alongside a strengthened balance sheet with cash and cash equivalents rising to over US$403 million. The surge in earnings was accompan...
HBM Holdings Sets Board Meeting to Approve 2025 Annual Results
Mar 18, 2026
HBM Holdings Limited has scheduled a board meeting for 30 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The meeting will also address any other business matters, signalling the upc...
HBM Wins China IND Nod for Long-Acting Atopic Dermatitis Antibody
Mar 9, 2026
HBM Holdings has reported that China’s National Medical Products Administration has approved the investigational new drug application for HBM7575, also known as SKB575, for the treatment of atopic dermatitis. The candidate is a long-acting b...
HBM Holdings Strikes Global Licensing and Equity Deal for HBM4003 with Solstice Oncology
Feb 23, 2026
HBM Holdings Limited has entered into an exclusive license and equity partnership agreement with Solstice Oncology, under which Solstice receives rights to develop and commercialize the clinical-stage asset HBM4003 outside Greater China. In return...
HBM Holdings Corrects Share Option Data Across Past Disclosures
Feb 16, 2026
HBM Holdings Ltd. has issued a clarification correcting clerical and calculation errors in previously published figures related to its share option scheme. The revisions affect disclosed numbers of shares available for grant, as well as outstandin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.